Efficacy of post‐induction therapy for high‐risk neuroblastoma patients with end‐induction residual disease

High‐risk neuroblastoma patients with end‐induction residual disease commonly receive post‐induction therapy in an effort to increase survival by improving the response before autologous stem cell transplantation (ASCT). The authors conducted a multicenter, retrospective study to investigate the efficacy of this approach.

[1]  S. Groshen,et al.  Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Mora,et al.  Naxitamab combined with granulocyte‐macrophage colony‐stimulating factor as consolidation for high‐risk neuroblastoma patients in complete remission , 2021, Pediatric Blood & Cancer.

[3]  A. Dumas,et al.  Long-term follow-up of high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell transplantation rescue , 2021, Bone Marrow Transplantation.

[4]  Wayne H. Liang,et al.  Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future. , 2020, JCO clinical cancer informatics.

[5]  K. McHugh,et al.  Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Servaes,et al.  Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Pierro,et al.  The Role of Surgery in High-risk Neuroblastoma , 2019, Journal of pediatric hematology/oncology.

[8]  A. Naranjo,et al.  Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. , 2019, JAMA.

[9]  A. Naranjo,et al.  Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG). , 2018, European journal of cancer.

[10]  K. Myers,et al.  High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma , 2018, Bone Marrow Transplantation.

[11]  A. Naranjo,et al.  Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  A. Naranjo,et al.  Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials , 2017, Cancer.

[13]  K. McHugh,et al.  Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Günter Schreier,et al.  Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. , 2017, The Lancet. Oncology.

[15]  D. von Allmen,et al.  Impact of Extent of Resection on Local Control and Survival in Patients From the COG A3973 Study With High-Risk Neuroblastoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  X. Paoletti,et al.  Outcome of children with relapsed or refractory neuroblastoma: A meta‐analysis of ITCC/SIOPEN European phase II clinical trials , 2017, Pediatric blood & cancer.

[17]  Rachel A. Kudgus,et al.  Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  S. Cohn,et al.  Genetic discoveries and treatment advances in neuroblastoma , 2016, Current opinion in pediatrics.

[19]  K. Matthay,et al.  Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG). , 2015, European journal of cancer.

[20]  Gudrun Schleiermacher,et al.  Advances in Risk Classification and Treatment Strategies for Neuroblastoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Julie R. Park,et al.  Neuroblastoma: paradigm for precision medicine. , 2015, Pediatric clinics of North America.

[22]  A. Naranjo,et al.  Semiquantitative mIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Children’s Oncology Group , 2013, The Journal of Nuclear Medicine.

[23]  K. Matthay,et al.  131I-Metaiodobenzylguanidine therapy in children with advanced neuroblastoma. , 2013, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[24]  F. Berthold,et al.  Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosis. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Gelfand,et al.  Pediatrics: diagnosis of neuroblastoma. , 2011, Seminars in nuclear medicine.

[26]  F. Berthold,et al.  Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Maris,et al.  Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  B. Brumback,et al.  Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  K. Do,et al.  Presalvage prostate‐specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy , 2006, Cancer.

[30]  K K Matthay,et al.  Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  S. Cohn,et al.  MYCN amplification remains prognostically strong 20 years after its "clinical debut". , 2004, European journal of cancer.

[32]  G. Severi,et al.  A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma , 2003, Cancer.

[33]  J. Peto,et al.  Asymptotically Efficient Rank Invariant Test Procedures , 1972 .

[34]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .